Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.
Type:
Grant
Filed:
July 29, 2022
Date of Patent:
March 26, 2024
Assignees:
Massachusetts Institute of Technology, Avalon GloboCare Corp.
Inventors:
Shuguang Zhang, David Jin, Rui Qing, Uwe Sleytr